The global market for metastatic castration-resistant prostate cancer (mCRPC) is projected to grow from USD 12.4 billion in 2024 to USD 20.8 billion by 2034, representing a compound annual growth rate (CAGR) of approximately 5.3%. This expansion is driven by rising prostate cancer incidence in aging populations, increased use of genomic profiling, and the adoption of novel therapies such as androgen receptor inhibitors, PARP inhibitors, radioligand therapies, and immunotherapies. Key players include Johnson & Johnson, Pfizer Inc., Astellas Pharma Inc., Bayer AG, Bristol Myers Squibb, Sanofi S.A., and Merck & Co. The Asia-Pacific region is expected to grow at the fastest rate (CAGR > 7%), while North America currently holds the largest market share (~47% in 2024). Challenges include treatment resistance, high drug costs, and limited access to genomic testing in emerging economies. Recent trends highlight the global approval of PSMA-targeted radioligand therapies, expansion of PARP inhibitor combinations, and the use of AI in imaging for improved detection and monitoring.

The global endometriosis market is projected to grow from USD 2.9 billion in 2024 to USD 5.4 billion by 2034, reflecting a compound annual growth rate (CAGR) of 6.6%. Driven by increased public awareness, advancements in diagnostic imaging and minimally invasive surgery, and the development of novel hormonal and non-hormonal therapies, the market is shifting toward patient-centric, long-term management strategies. Key growth drivers include global awareness campaigns, therapeutic innovation such as selective progesterone receptor modulators (SPRMs) and oral GnRH antagonists, integration of fertility treatments like IVF, and technological innovations including AI-powered diagnostics. Major players include AbbVie Inc., Bayer AG, Pfizer Inc., Myovant Sciences, AstraZeneca plc, Johnson & Johnson, Takeda Pharmaceutical Company Ltd., Roche Diagnostics, and Eli Lilly and Company. Regional dynamics show North America leading in market size and access, while Asia-Pacific is the fastest-growing region due to expanding healthcare infrastructure and rising awareness. Challenges remain, including delayed diagnosis (average of 7–10 years), high treatment costs, and recurrence rates after surgery.

The endometriosis market is projected to grow significantly through 2034, driven by increasing prevalence, awareness, and new treatments. Key developments include the discontinuation of a drug candidate by Organon, approval of a new NHS treatment for endometriosis, and clinical trials for innovative therapies like HMI-115 and MET. The market is dominated by companies such as AbbVie, Pfizer, and Neurocrine Biosciences, with a focus on drug development, diagnostic tools, and treatment options.

The Endometriosis market is forecasted to grow significantly through 2034, as highlighted by DelveInsight. The report analyzes the market's epidemiology, therapies, and drivers, including rising prevalence, R&D investment, and new diagnostic tools. Key companies include Ferring Pharma, AbbVie, Myovant, and others, while therapies like ORILISSA and MYFEMBREE are discussed. The report covers 7MM markets (US, EU5, Japan) from 2020–2034.

BBOT, a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, has appointed Uneek Mehra as Chief Financial Officer. Mehra, a seasoned financial executive with over 28 years of experience in biotech and healthcare, previously held leadership roles at companies like 4DMT, Myovant Sciences, and Novartis.